NAMD Letter Urges Congress to Address Break Through Drugs

Today the National Association of Medicaid Directors sent the attached letter to the leaders of the Senate Finance and HELP and House Energy & Commerce and Ways & Means committees regarding the current situation with break through prescription drug treatments. The letter addresses the challenges presented by new hepatitis C treatments. It focuses on issues pertinent to state Medicaid programs, though it recognizes this issue impacts all government programs and other payers as well as patients. It also calls on Members of Congress to begin a dialogue on break through drug pricing issues and to advance pragmatic solutions that balance the needs of patients and the costs for Medicaid.

Read the full letter here.

Comments are closed.